Aera Therapeutics, a biotechnology company harnessing next-generation enabling delivery technologies and precision payloads to unlock the full potential of genetic medicines, today presented ...
New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL ...
The News-Times on MSN
Builder’s plan to add 12 homes to gated community near Danbury High School gets environmental review
The proposed area of development consists of a relatively flat, partially cleared ridgetop with steeper, wooded side slopes ...
CD19-targeting UB-VV11 became the first in vivo CAR-T cell therapy to be cleared for human testing by the FDA last year, and ...
First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Participants Date & Time : Oct.
The FDA has granted fast track designation to UB-VV111 for the treatment of relapsed/refractory large B-cell lymphoma (LBCL) following 2 or more prior lines of therapy and relapsed/refractory chronic ...
Genmab acquires Merus for $8bn, adding promising oncology asset petosemtamab. Check out my thoughts on this deal and my ...
Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the ...
Post-CAR T infection prophylaxis should follow European Hematology Association/European Society for Blood and Marrow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback